126 completed, 30 terminated, 15 recruiting, 14 unknown. 95 Phase 1, 84 Phase 2, 18 Not applicable, 16 Phase 3, 1 Early Phase 1.
Follow Leukemia, Prolymphocytic: new trials by email Literature Review of Leukemia, Prolymphocytic trials Research Report on Leukemia, Prolymphocytic
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase Ib/II Trial of Cladribine/Ruxolitinib/Venetoclax in Patients With Relapsed/Refractory T-cell Prolymphocytic Leukemia Ruxolitinib, Cladribine, Venetoclax - T-cell Prolymphocytic Leukemia, Refractory T-Cell Prolymphocytic Leukemia | Phase 1 / Phase 2 | Recruiting | M.D. Anderson Cancer Center | 36 | 2026-04-28 | 2026-08-12 |
| Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma Ruxolitinib, Positron emission tomography-computed tomography, Bone Marrow Biopsy - T-cell Lymphoma, Graft Versus Host Disease | Phase 2 | Recruiting | Jonathan Brammer | 44 | 2026-02-12 | 2026-04-15 |
| Duvelisib and Venetoclax in Patients With Relapsed or Refractory Peripheral T-cell Lymphoma (PTCL) Duvelisib, Venetoclax - T-cell-prolymphocytic Leukemia, Cutaneous T-Cell Lymphoma Refractory | Phase 1 / Phase 2 | Recruiting | Jonsson Comprehensive Cancer Center | 12 | 2025-05-02 | 2026-07-17 |
| Sequential CAR-T Cells Therapy for CD5/CD7 Positive T-cell Acute Lymphoblastic Leukemia and Lymphoblastic Lymphoma Using CD5/CD7-Specific CAR-T Cells CD5/CD7 CAR-T - T Cell Lymphoma, T Cell Leukemia | Phase 1 / Phase 2 | Recruiting | Essen Biotech | 60 | 2024-07-10 | 2024-11-12 |
| HLA-Mismatched Unrelated Donor Peripheral Blood Stem Cell Transplantation With Reduced Dose Post Transplantation Cyclophosphamide GvHD Prophylaxis Busulfan, Fludarabine, PBSC Hematopoietic Stem Cell Transplantation (HSCT) - Acute Lymphoblastic Leukemia, Acute Myeloid Leukemia | Phase 2 | Active not recruiting | Center for International Blood and Marrow Transplant Research | 313 | 2023-12-08 | 2026-08-17 |
| Dose-Escalation and Dose-Expansion Study to Evaluate the Safety and Tolerability of Anti-CD7 Allogeneic CAR T-Cells (WU-CART-007) in Patients With CD7+ Hematologic Malignancies WU-CART-007 - T-Cell Non-Hodgkin Lymphoma, Acute Myeloid Leukemia | Phase 1 | Suspended | Washington University School of Medicine | 6 | 2023-10-10 | 2026-07-21 |
| A Registry for People With T-cell Lymphoma Optional Blood Sample and Nail Sample - T-cell Lymphoma, NK-Cell Lymphoma | Recruiting | Memorial Sloan Kettering Cancer Center | 1000 | 2023-07-27 | 2026-05-20 | |
| Itacitinib With High-dose Posttransplantation Cyclophosphamide in Older Patients Itacitinib - Leukemia, Acute, Myelodysplastic Syndromes | Phase 1 | Active not recruiting | Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins | 32 | 2023-07-06 | 2026-10-07 |
| Allo HSCT Using RIC and PTCy for Hematological Diseases Peripheral Blood Stem Cell Transplant, Allopurinol 300 MG, Fludarabine - Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 2 | Recruiting | Masonic Cancer Center, University of Minnesota | 56 | 2023-05-01 | 2026-07-06 |
| Genetically Engineered Cells (Anti-CD19/CD20/CD22 CAR T-cells) for the Treatment of Relapsed or Refractory Lymphoid Malignancies Anti-CD19/CD20/CD22 CAR T-Cells, Cyclophosphamide, Fludarabine Phosphate - Recurrent Acute Lymphoblastic Leukemia, Recurrent B Acute Lymphoblastic Leukemia | Phase 1 | Recruiting | Sumithira Vasu | 54 | 2022-06-30 | 2026-05-29 |
| Safety, PK, PD, Clinical Activity of KT-333 in Adult Patients With Refractory Lymphoma, Large Granular Lymphocytic Leukemia, Solid Tumors KT-333 - Non Hodgkin Lymphoma (NHL), Peripheral T-cell Lymphoma (PTCL) | Phase 1 | Completed | Kymera Therapeutics, Inc. | 56 | 2022-05-19 | 2025-03-19 |
| Study of Oral Administration of LP-118 in Patients With Relapsed or Refractory CLL, SLL, MDS, MDS/MPN, AML, CMML-2, MPN-BP, ALL, MF, NHL, RT, MM or T-PLL. LP-118 - Non Hodgkin Lymphoma, Richter Transformation | Phase 1 | Recruiting | Newave Pharmaceutical Inc | 100 | 2022-05-08 | 2026-05-05 |
| A Study of Ruxolitinib and Duvelisib in People With Lymphoma Ruxolitinib, Duvelisib - T-cell Lymphomas, NK-Cell Lymphomas | Phase 1 | Recruiting | Memorial Sloan Kettering Cancer Center | 70 | 2021-08-12 | 2026-09-09 |
| A Study Evaluating APG-115 as a Single Agent or in Combination With APG-2575 in Subjects With R/R T-PLL and NHL APG-115, APG-2575 - T-Prolymphocytic Leukemia, Non-Hodgkins Lymphoma | Phase 2 | Recruiting | Ascentage Pharma Group Inc. | 78 | 2021-07-12 | 2025-11-04 |
| Anti-CD7 CAR-Engineered T Cells for T Lymphoid Malignancies Malignancies Fludarabine + Cyclophosphamide + CAR7-T Cells - T-Cell Lymphocytic Leukemia, T-Cell Chronic Lymphocytic Leukemia | Phase 1 | Unknown | Union Hospital, Tongji Medical College, Huazhong University of Science and Technology | 24 | 2021-04-15 | 2022-03-16 |
| Fludarabine, Cytarabine, and Pegcrisantaspase for the Treament of Relapsed or Refractory Leukemia Cytarabine, Fludarabine, Pegcrisantaspase - Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Recurrent Acute Biphenotypic Leukemia | Phase 1 | Terminated | M.D. Anderson Cancer Center | 19 | 2021-04-09 | 2024-12-12 |
| Donor Stem Cell Transplant With Treosulfan, Fludarabine, and Total-Body Irradiation for the Treatment of Hematological Malignancies Allogeneic Hematopoietic Stem Cell Transplantation, Cyclophosphamide, Cyclosporine - Acute Leukemia, Acute Lymphoblastic Leukemia | Phase 2 | Recruiting | Fred Hutchinson Cancer Center | 60 | 2021-01-25 | 2026-05-29 |
| Letermovir for the Prevention of Cytomegalovirus Reactivation in Patients With Hematological Malignancies Treated With Alemtuzumab Letermovir - B-Cell Prolymphocytic Leukemia, Chronic Lymphocytic Leukemia | Phase 2 | Completed | Ohio State University Comprehensive Cancer Center | 6 | 2020-09-15 | 2025-02-28 |
| Observatory of Prolymphocytic Leukemia T Molecular caracterization - Prolymphocytic Leukemia, T-cell Leukemia | Active not recruiting | French Innovative Leukemia Organisation | 50 | 2020-07-01 | 2026-10-19 | |
| Itacitinib and Alemtuzumab in Treating Patients With T-Cell Prolymphocytic Leukemia Alemtuzumab, Itacitinib - Recurrent T-Cell Prolymphocytic Leukemia, T-Cell Prolymphocytic Leukemia | Phase 1 | Completed | M.D. Anderson Cancer Center | 15 | 2020-01-15 | 2024-10-10 |
Showing 20 of 208. Sign in to see all of them.
Leukemia, Lymphocytic, Chronic, B-Cell (181) · Lymphoma, Follicular (129) · Lymphoma, Mantle-Cell (129) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (123) · Lymphoma, Large B-Cell, Diffuse (112) · Lymphoma, B-Cell, Marginal Zone (111) · Lymphoma, Non-Hodgkin (107) · Leukemia, Myeloid, Acute (105) · Burkitt Lymphoma (100) · Leukemia (100) · Hodgkin Disease (97) · Multiple Myeloma (96) · Waldenstrom Macroglobulinemia (87) · Lymphoma (86)
Hemic and Lymphatic Diseases (208) · Immune System Diseases (207) · Immunoproliferative Disorders (207) · Leukemia, Lymphoid (207) · Lymphatic Diseases (207) · Neoplasms by Histologic Type (207) · Hematologic Diseases (205) · Disease Attributes (187) · Neoplasms (187) · Pathologic Processes (187) · Pathological Conditions, Signs and Symptoms (187) · Lymphoproliferative Disorders (184) · Chronic Disease (183) · Leukemia, B-Cell (181) · Lymphoma, B-Cell (130)
fludarabine phosphate (45) · Cyclophosphamide (36) · Mycophenolic Acid (26) · Whole-Body Irradiation (24) · Peripheral Blood Stem Cell Transplantation (22) · fludarabine (18) · Cyclosporine (17) · Rituximab (16) · Tacrolimus (16) · Antilymphocyte Serum (14) · Busulfan (13) · Cyclosporins (10) · Filgrastim (10) · Methotrexate (8) · Cytarabine (7)
National Cancer Institute (NCI) (18) · Fred Hutchinson Cancer Center (17) · M.D. Anderson Cancer Center (15) · Masonic Cancer Center, University of Minnesota (12) · Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins (7) · Memorial Sloan Kettering Cancer Center (6) · Alliance for Clinical Trials in Oncology (5) · Case Comprehensive Cancer Center (5) · City of Hope Medical Center (5) · Jonsson Comprehensive Cancer Center (5) · Chinese PLA General Hospital (4) · European Organisation for Research and Treatment of Cancer - EORTC (4) · German CLL Study Group (4) · Northside Hospital, Inc. (4) · Ohio State University Comprehensive Cancer Center (4)
United States (171) · Germany (11) · China (10) · Italy (9) · France (7) · Switzerland (6) · United Kingdom (5) · Belgium (4) · Canada (4) · Denmark (3) · Slovakia (3) · Turkey (Türkiye) (3) · Australia (2) · Austria (2) · Israel (2)
Mohamed Sorror (4) · Robert Kreitman, MD (4) · Asad Bashey, MD, PhD (3) · Claudio G. Brunstein, MD, PhD (3) · David Maloney (3) · Jennifer Woyach, MD (3) · John A. Glaspy, MD, MPH (3) · Roger Strair, MD, PhD (3) · Scott R. Solomon, MD (3) · Tapan Kadia, MD (3) · Brenda Sandmaier (2) · Charles A. Linker, MD (2) · Chitra Hosing (2) · Claudio Brunstein, MD (2) · Claudio Brunstein, MD, PhD (2)
PMID 32499241, PMID 34515338, PMID 28054442, PMID 28714866, PMID 34608724, PMID 10552943, PMID 10764422, PMID 11986207, PMID 15459300, PMID 16061911, PMID 16710026, PMID 17020988, PMID 17397698, PMID 17640728, PMID 18698002, PMID 18997171, PMID 19170225, PMID 19672771, PMID 19706886, PMID 19826119, PMID 19841031, PMID 20674758, PMID 20952687, PMID 21173095, PMID 21296675, PMID 21756035, PMID 22259028, PMID 22289993, PMID 22480131, PMID 23358983, PMID 23512246, PMID 23524863, PMID 23810788, PMID 24474568, PMID 24990615, PMID 25317870, PMID 25444722, PMID 25596730, PMID 26175532, PMID 26182309, PMID 26210442, PMID 26389849, PMID 26451310, PMID 26641137, PMID 26659919, PMID 26700120, PMID 26700123, PMID 26853648, PMID 26943915, PMID 27020837
P30CA015704 (12), P01CA018029 (6), P30CA016058 (6), U01CA076576 (6), P30CA006973 (5), P30CA072720 (5), P30CA016086 (4), P30CA016672 (4), P30CA043703 (3), U10CA031946 (3), N01CM62207 (2), P01CA078902 (2), P30CA015083 (2), P30CA022453 (2), P30CA033572 (2)